Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Income towards Parent Company: 2017-2024

Historic Income towards Parent Company for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$43.2 million.

  • Kiniksa Pharmaceuticals International's Income towards Parent Company rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 142.99%. This contributed to the annual value of -$43.2 million for FY2024, which is 28.48% up from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's Income towards Parent Company is -$43.2 million, which was up 28.48% from -$60.4 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Income towards Parent Company's 5-year high stood at $267.4 million during FY2022, with a 5-year trough of -$167.1 million in FY2020.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Income towards Parent Company averaged around $54.6 million, with its median value being -$43.2 million (2024).
  • In the last 5 years, Kiniksa Pharmaceuticals International's Income towards Parent Company skyrocketed by 261.42% in 2022 and then tumbled by 122.58% in 2023.
  • Yearly analysis of 5 years shows Kiniksa Pharmaceuticals International's Income towards Parent Company stood at -$167.1 million in 2020, then rose by 0.88% to -$165.7 million in 2021, then spiked by 261.42% to $267.4 million in 2022, then slumped by 122.58% to -$60.4 million in 2023, then grew by 28.48% to -$43.2 million in 2024.